Skip to Main Content
+1 (508) 881-6771
0
Menu Button

Melanoma

668

RECONSTRUCTED HUMAN SKIN MODEL TO STUDY MELANOMA AT DIFFERENT STAGES OF PROGRESSION.

The incidence of cutaneous melanoma (CM) has dramatically increased in the last few decades.  The changes leading from treatable radial growth phase (RGP) melanoma, to high risk vertical growth phase (VGP), and finally to the metastatic melanoma (MM) phenotype are not well understood.  Development of specific RGP, VGP, and MM tissue models along with their […]
703

FISETIN INHIBITS HUMAN MELANOMA CELL INVASION THROUGH PROMOTION OF MESENCHYMAL TO EPITHELIAL TRANSITION AND BY TARGETING MAPK AND NFкB SIGNALING PATHWAY.

Malignant melanoma is a serious form of cancer responsible for approximately 80% of skin cancer-related deaths. Activating mutations in the serine/threonine kinase BRAF occur in 60-70% of malignant melanomas. Preclinical studies have demonstrated that BRAF plays an important role in regulating the MAPK signaling cascade in melanoma. The RAF-MEK-ERK (MAPK) pathway is the key regulator […]
754

THE INCLUSION COMPLEX OF 4-HYDROXYNONENAL WITH A POLYMERIC DERIVATIVE OF Β-CYCLODEXTRIN ENHANCES THE ANTITUMORAL EFFICACY OF THE ALDEHYDE IN SEVERAL TUMOR CELL LINES AND IN A THREE-DIMENSIONAL HUMAN MELANOMA MODEL.

4-Hydroxynonenal (HNE) is the most studied end product of the lipoperoxidation process, by virtue of its relevant biological activity. The antiproliferative and proapoptotic effects of HNE have been widely demonstrated in a great variety of tumor cell types in vitro. Thus, it might represent a promising new molecule in anticancer therapy strategies. However, the extreme […]
734

GOSSYPIN AS A NOVEL SELECTIVE DUAL INHIBITOR OF V-RAF MURINE SARCOMA VIRAL ONCOGENE HOMOLOG B1 AND CYCLIN-DEPENDENT KINASE 4 FOR MELANOMA

Mutation in the BRAF gene (BRAFV600E) exists in nearly 70% of human melanomas. Targeted therapy against BRAFV600E kinase using a recently identified RAF-selective inhibitor, PLX4032, has been successful in early clinical trials. However, in patients with the normal BRAF allele (wild-type), PLX4032 is protumorigenic. This conundrum identifies the unmet need for novel therapeutic agents to […]
728

THE ROLE OF MELANOMA TUMOR-DERIVED NITRIC OXIDE IN THE TUMOR INFLAMMATORY MICROENVIRONMENT: ITS IMPACT ON THE CHEMOKINE EXPRESSION PROFILE, INCLUDING SUPPRESSION OF CXCL10.

Melanoma appears to be heterogeneous in terms of its molecular biology, etiology and epidemiology. We previously reported that the expression of inducible nitric-oxide synthase (iNOS) in melanoma tumor cells is strongly correlated with poor patient survival. Therefore, we hypothesized that nitric oxide (NO) produced by iNOS promotes the melanoma inflammatory tumor microenvironment associated with poor […]
365

RECONSTRUCTED HUMAN SKIN MODEL TO STUDY MELANOMA AT DIFFERENT STAGES OF PROGRESSION.

This study by scientists at MatTek Corp. demonstrated that MatTek’s EpiDerm-FT in vitro human full-thickness skin tissue equivalent can be co-cultured with melanocytes at different stages of malignancy to produce three dimensional, serum-free tissue culture models that can be used to study, understand, and develop preventative and therapeutic treatments for cutaneous melanoma. The incidence of […]
326

HUMAN MELANOMA DEVELOPMENT IN RECONSTRUCTED SKIN MODELS.

Human skin reconstructs are three dimensional in vitro models consisting of a co-culture of epidermal keratinocytes and melanocytes plated onto a dermal substrate. In contrast to cells in monolayer culture, tissue-engineered skin equivalents contain well-developed epidermal layers with normal melanocytes being distributed at the basement membrane that separates the epidermis from the dermis. The incidence […]
525

UPREGULATION OF SOX9 INHIBITS THE GROWTH OF HUMAN AND MOUSE MELANOMAS AND RESTORES THEIR SENSITIVITY TO RETINOIC ACID.

This study by researchers at the National Cancer Institute (NIH) demonstrated that MatTek’s Melanoma in vitro human skin tissue equivalent can be used to investigate both the efficacy and cytotoxicity of potential malignant melanoma treatments. Treatments for primary and metastatic melanomas are rarely effective. Even therapeutics such as retinoic acid that are successfully used to […]
498

A SMALL-MOLECULE E2F INHIBITOR BLOCKS GROWTH IN A MELANOMA CULTURE MODEL.

This study by researchers at the H. Lee Moffitt Cancer Center and Research Institute demonstrated how MatTek’s Melanoma in vitro human skin tissue equivalent can be used to investigate both the efficacy of potential melanoma therapeutic agents and their potential toxicity on non-melanoma skin cells. HLM006474 was identified using a computer-based virtual screen and the […]
455

ROSCOVITINE INHIBITS DIFFERENTIATION AND INVASION IN A THREE-DIMENSIONAL SKIN RECONSTRUCTION MODEL OF METASTATIC MELANOMA.

This study by researchers at the H. Lee Moffitt Cancer Center and Research Institute, and the Mitchell Cancer Institute (Univ. of South Alabama) demonstrated that the MatTek 3-D Melanoma Tissue Model can be used to investigate the therapeutic potential of drugs designed to help patients with metastatic melanoma – in this study, the drug was […]
618

PROTEOMIC ANALYSIS OF LASER MICRODISSECTED MELANOMA CELLS FROM SKIN ORGAN CULTURES.

Gaining insights into the molecular events that govern the progression from melanoma in situ to advanced melanoma and understanding how the local microenvironment at the melanoma site influences this progression are two clinically pivotal aspects that to date are largely unexplored. In an effort to identify key regulators of the crosstalk between melanoma cells and […]